ASX ANNOUNCEMENT

ARGENICA GRANTED NEW US PATENT FOR SURGICALLY INDUCED STROKE

Perth, Australia; 22 May, 2025 - Argenica Therapeutics Limited (ASX: AGN) ("Argenica" or the "Company"), a clinical stage biotechnology company developing novel therapeutics to reduce brain tissue death after brain injury, is pleased to announce the granting of a new US patent (patent number 12,303,550) entitled "Neuroprotective Peptides" by the United States Patent Office (USPTO). This patent was filed with the USPTO as a divisional application and follows the granting of the parent patent by the USPTO.

The new US patent extends the scope of the Company's earlier parent patent filing by covering the specific use of Argenica's neuroprotective peptides in a **method of treating a surgery patient at risk of suffering cerebral ischaemia or stroke.** This protection is especially relevant in high-risk cardiac and vascular operations—such as proximal thoracic-aortic repairs and valve replacements—where peri-operative stroke rates can be up to 10 % above baseline. The excess risk is driven largely by emboli: tiny fragments of clot, calcium, or other debris that can enter the bloodstream during surgery, lodge in cerebral vessels, and block blood flow to the brain, resulting in stroke.

The new patent builds on the protection provided by Argenica's previously granted parent patent for novel neuroprotective peptides covering a broad range of neurological conditions including, but not limited to, ischaemic stroke, traumatic brain injury, hypoxic ischaemic encephalopathy. The expiry date of the parent and divisional patents is 30 October 2034.

Dr Liz Dallimore, **Managing Director of Argenica**, commented "Our new divisional US patent further strengthens Argenica's already wide-ranging protection for neuroprotective peptides. Because stroke is a significant complication after cardiac and other major surgeries, the patent creates an additional clinical and commercial avenue for our lead candidate, ARG-007, and expands the overall potential of this promising neuroprotective drug."

Argenica is advancing ARG-007 through clinical development for acute ischaemic stroke, with an initial focus on patients presenting to the emergency-department having suffered a large-vessel occlusion. Top-line data from the Phase 2 clinical trial are expected in Q3 2025; if positive, they will confirm ARG-007's neuroprotective action in ischaemic stroke and bolster its promise for preventing surgery-related strokes as well.

This announcement has been approved for release by the Board of Argenica

For more information please contact: info@argenica.com.au

ABOUT ARGENICA

Argenica (ASX: AGN) is developing novel therapeutics to reduce brain tissue death after stroke and other types of brain injury and neurodegenerative diseases to improve patient outcomes. Our lead neuroprotective peptide candidate, ARG-007, has been successfully demonstrated to improve outcomes in pre-clinical stroke models, traumatic brain injury (TBI) and hypoxic ischaemic encephalopathy (HIE). The Company has completed a Phase 1 clinical trial in healthy human volunteers to assess the safety and tolerability of a single dose of ARG-007. Argenica has now completed dosing in a Phase 2 clinical trial in ischaemic stroke patients, and continues to generate preclinical data in other neurological conditions, including in TBI and HIE.